Sales and Marketing

Showing 15 posts of 11526 posts found.

NICE says yes to Tasigna for resistant disease

January 13, 2012 Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna

NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …

AstraZeneca does data deal

January 13, 2012 Sales and Marketing AstraZeneca, IMS Health, data

AstraZeneca has signed a deal with an information company in a bid to improve the data it has on how …

Novartis to cut 2,000 US jobs

January 13, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Diovan, Novartis, job cuts

Novartis will slash 1,960 jobs in the US as it prepares for life without its blockbuster medicine Diovan. The hypertension …

Pharma unprepared for annus horribilis

January 12, 2012 Research and Development, Sales and Marketing AZ, Pfizer, Takeda, patents, pharma

A new survey shows pharma is not prepared to deal with the tough year ahead as many blockbuster drugs begin …

Glide Pharma appoints Dr Ian Smith as its new chief executive

January 12, 2012 Business Services, Manufacturing and Production, Sales and Marketing

Glide Pharma, a firm focused on the needle-free administration of solid dose therapeutics and vaccines, has appointed Dr Ian Smith …
NICE picture

NICE rejects Sanofi’s Jevtana

January 12, 2012 Sales and Marketing Jevtana, NICE, Sanofi, Zytiga

NICE is not recommending Sanofi’s prostate cancer drug Jevtana due to its high cost and questions over its safety. In …

NICE guidance to be enforced, says Lansley

January 11, 2012 Sales and Marketing NHS, NICE, PCTs, black lists, prescribing

Local NHS organisations will no longer be allowed to ‘ban’ drugs recommended by NICE, the health secretary has said.England’s primary …

Crisis in the boardroom: 2011’s most dramatic departures

January 11, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, KV pharmaceuticals, Kindler, Pfizer, management

In December 2010, Jeffrey Kindler, the chief executive of Pfizer suddenly announced his departure from the company.His abrupt exit made …

Richard Barker joins Aegate as a senior advisor

January 11, 2012 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Aegate, Richard Barker

Aegate’s board of directors have announced that the previous director general of the ABPI has joined the company as a …

Underwhelming results for GSK’s Relovair

January 10, 2012 Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma

GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …

NICE set to reject Xarelto in AF

January 10, 2012 Sales and Marketing AF, NICE, Pradaxa, Xarelto, atrial fibrillation

NICE says it needs more data on Bayer’s Xarelto in order to recommend it for people with atrial fibrillation. The …

Andrew Roberts joins Apodi senior management team

January 10, 2012 Business Services, Sales and Marketing Andrew Roberts

Apodi has bolstered its senior management team with the arrival of Andrew Roberts as director of Business and Partnership Development. …

Study supports GLP-1 agonists for weight loss

January 10, 2012 Research and Development, Sales and Marketing GLP-1, Novo Nordisk, Sanofi, diabetes, lilly

An independent study by academics has concluded that GLP-1 agonist drugs help patients to lose weight – with the effect …

BMS to buy hep C firm Inhibitex for $2.5 billion

January 9, 2012 Research and Development, Sales and Marketing BMS, Inhibitex, hep C

Bristol-Myers Squibb will acquire virology specialist Inhibitex for $2.5 billion, expanding its infectious disease portfolio. Bristol-Myers Squibb will acquire the …
AstraZeneca image

AstraZeneca leaks confidential information

January 9, 2012 Sales and Marketing AstraZeneca, data leak

There have been red faces at AstraZeneca after the company sent confidential information to analysts by mistake.  It was forced …
The Gateway to Local Adoption Series

Latest content